|
False Claims Act Update & Alert |
||||||
|
Taxpayers
Against Fraud Education Fund | Washington, D.C. |
WWW.TAF.ORG
|
||||||
| . | ||||||
| . | ||||||
n TAF Home Page n Previous Newsletters n Email editor
|
 AstraZeneca
to Pay $520 Million AstraZeneca has agreed to pay $520 million to settle a False Claims Act case charging the company with off-label marketing of the atypical anti-psychotic drug Seroquel. In this settlement, the federal government will receive $302 million and the states will receive $218 million. The two relators in the case were Dr. Stefan Kruszewski and James Wetta. This is the largest purely civil off-label marketing settlement. >> To read the complaint and settlement |
|||||
 Ortho-McNeil
to Pay $81 MillionOrtho-McNeil has agreed to pay $81 million to settle a False Claims Act case charging the company with paying kickbacks for doctors for prescribing the anti-seizure medication, Topamax, for such off-label uses such as eating disorders, weight loss, and alcohol dependence. Angela Maher and Anastasia Savka-Klovski and Dr. Gary R. Spivack will share in the whistleblower awards. >> to read the complaint and settlement |
||||||
 Schwarz
to Pay $22 MillionSchwarz Pharma will pay $22 million to settle a False Claims Act case charging the company with marketing two unapproved drugs, Deponit and Hyoscyamine Sulfate ER. Under the settlement, two whistleblowers, Constance and James Conrad will receive a total of $1,836,575 from the federal share and an additional sum from the states. |
||||||
 Grassley
Cautions OIG, States
Sen. Grassley has sent
a strongly worded letter
to HHS and DoJ underscoring the fact that he thinks a
"first-to-file-anywhere bar" being suggested to the states by
pharma lobbyists should disqualify a state from receiving any
Deficit Reduction Act incentive for having a state FCA.
|
||||||
|
|
||||||
| . | ||||||